A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Oral CP-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis

Trial Profile

A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Oral CP-690,550 As An Induction Therapy In Subjects With Moderate To Severe Ulcerative Colitis

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms OCTAVE; OCTAVE Induction 1
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Nov 2017 Results of an integrated analysis assessing safety of Tofacitinib in NCT00787202, NCT01458574, NCT01458951, NCT01465763 and NCT01470612 (n=1240) presented at the 25th United European Gastroenterology Week
    • 01 Nov 2017 Results of pooled analysis assessing pregnancy outcomes data from four studies (OCTAVE Induction 1, OCTAVE Induction 2, Sustain and OCTAVE long-term) presented at the 25th United European Gastroenterology Week.
    • 16 Oct 2017 According to a Pfizer media release, data will be presented at the World Congress of Gastroenterology at the American College of Gastroenterology (WCOG at ACG2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top